Precigen FY2025 EPS Estimate Reduced by Cantor Fitzgerald

Precigen, Inc. (NASDAQ:PGEN - Free Report) - Equities research analysts at Cantor Fitzgerald lowered their FY2025 earnings per share estimates for Precigen in a research note issued to investors on Thursday, May 15th. Cantor Fitzgerald analyst J. Kim now forecasts that the biotechnology company will post earnings of ($0.37) per share for the year, down from their previous estimate of ($0.27). Cantor Fitzgerald currently has a "Overweight" rating on the stock. The consensus estimate for Precigen's current full-year earnings is ($0.32) per share.

Several other research firms have also recently commented on PGEN. HC Wainwright reaffirmed a "buy" rating and set a $6.00 price objective on shares of Precigen in a research report on Thursday, March 20th. Wall Street Zen cut Precigen from a "hold" rating to a "sell" rating in a research report on Saturday. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $7.00.

Precigen Stock Performance

Shares of NASDAQ PGEN traded down $0.02 during midday trading on Monday, hitting $1.37. 1,408,452 shares of the company traded hands, compared to its average volume of 1,328,964. Precigen has a 12-month low of $0.65 and a 12-month high of $2.17. The stock has a 50-day moving average price of $1.46 and a 200 day moving average price of $1.32. The firm has a market cap of $404.40 million, a P/E ratio of -2.49 and a beta of 1.82.

Precigen (NASDAQ:PGEN - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported ($0.07) EPS for the quarter, topping analysts' consensus estimates of ($0.08) by $0.01. Precigen had a negative return on equity of 123.06% and a negative net margin of 3,521.68%. The company had revenue of $1.34 million during the quarter, compared to analyst estimates of $0.50 million.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. BNP Paribas Financial Markets purchased a new position in Precigen in the fourth quarter worth about $27,000. Envestnet Asset Management Inc. boosted its position in Precigen by 29.0% in the fourth quarter. Envestnet Asset Management Inc. now owns 26,343 shares of the biotechnology company's stock worth $30,000 after purchasing an additional 5,915 shares during the last quarter. Boothbay Fund Management LLC purchased a new position in Precigen in the fourth quarter worth about $35,000. Apella Capital LLC purchased a new position in Precigen in the first quarter worth about $40,000. Finally, RPO LLC purchased a new position in Precigen in the fourth quarter worth about $47,000. 33.51% of the stock is owned by hedge funds and other institutional investors.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.